Called climbing the corporate ladder when common 2 bit punk basher becomes head "handler" of 3 or more cubicles and / or computer terminals.
bd - it took Schweity 5 months to review the pipeline and give us the "plan" for a GBM trial which he cancelled 3 months later - does it surprise you the data is delayed?
mano - I wouldn't say there's a risk of the trial being delayed, I would say it's a given. The oxi4503 Phase I took about 3 years .... yes, they should get the trial running and put the company for sale
I'd figure almost 3.5 years from today cause it may be 3 more months before it gets running. If positive another year after that to analyze results and submit an NDA, then another 10 months for approval, 6 months later a launch and another half year later before any appreciable sales are recognized ... let's say 2022 approximately give or take a year ...
In my mind that's the critical question, if they can then we have inherent value in the partnership and resources to see the trial to completion. If they start with a "go it alone" strategy hoping to partner after some interim data readouts that's problematic as the start of the trial and first readouts are far enough away that cash could start to become a concern. Then they are bargaining on weakness and the hedgies will smell blood on a need to finance and start turning the screws on Loar. It could spell near term trouble, that's for sure, these guys and Investors need a break.
That's why he's going to BIO, he already has a deal and they need to shake hands, ink the paper and have drinks ... maybe? Just speculation of course ...
Wonder if Roche has turned their back now that they have Avastin approved for OC in the US? Now the 180 switcheroo to include Chemo in our Phase II / III, maybe they are trying to attract Roche back to the marriage before they have to pay the catering bill?
Could be drob, but that would probably have to come after some interim results which would likely be 1 year after the start, I don't think anyone has confidence to licence based on just the one GOG186i result. Maybe in 2017 partnerships will become a reality?
Right here Mano - “We have engaged a well-qualified clinical research organization to assist us with this trial, and intend to begin patient enrollment in the second quarter of this year"